Login to Your Account



SARcode's Dry Eye Drug Hits Endpoint in First Phase III Trial

By Jennifer Boggs
Managing Editor

Tuesday, October 23, 2012
SARcode Bioscience Inc. cleared the first hurdle in its Phase III program testing dry eye candidate lifitegrast, with the drug nailing its primary endpoint in the first pivotal trial, demonstrating biologic activity against ocular surface damage.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription